Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999268 | 1.00 | MEN1 (0.38) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL1000881 | 1.00 | MEN1 (0.38) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL999270 | 1.00 | MEN1 (0.38) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL1000335 | 0.95 | MEN1 (0.40) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL998660 | 0.95 | MEN1 (0.40) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL1000235 | 0.88 | MAPK1 (0.41) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL999775 | 0.85 | NPC1 (0.36) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL999776 | 0.85 | NPC1 (0.36) | MEN1KMT2AMAPTL3MBTL1KDM4E | |
| SCHEMBL999845 | 0.81 | CCNE2 (0.39) | MAPTL3MBTL1SMN1; SMN2ALDH1A1HTR2A | |
| SCHEMBL998399 | 0.81 | CCNE2 (0.39) | MAPTL3MBTL1SMN1; SMN2ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
| US-7851636-B2 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | NOVO NORDISK A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| US-7598391-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2009-10-06 | — | — | US | disclosed |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | MEN1 3458/4885KMT2A 2496/4885MAPT 1590/4885 |
| US-20090216013-A1 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | MEN1 2364/4885KMT2A 2976/4885MAPT 2579/4885 |
| US-20100204288-A1 | {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial; antidiabetic agents | GCK, GCKR, HK1 | MEN1 2737/4885KMT2A 3750/4885MAPT 2142/4885 |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | MEN1 2082/4885KMT2A 2281/4885MAPT 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.